Esperion Therapeutics Inc. has a tough hill to climb if it gets to market with its cholesterol therapy bempedoic acid, a feat that has proven challenging for the highly effective PCSK9 inhibitors. The company is betting that if the drug costs payers and patients less than the injectable PCSK9 inhibitors that will help it gain traction.
Esperion is aiming for an annual list price of $3,500 and now is guiding for a net price of about...




